Biotech entity
Coverage clusters in pharma, which accounts for 8 of those 10, with the remainder spread across 2 other categories. They are less corroborated than the beat average, carrying 2.1 original sources each against 3.4 for the same window. Negative sentiment reaches 20% here, compared with 16% across the 785-story beat baseline for the same window.
Last mentioned: 1d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 10 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Coverage clusters in pharma, which accounts for 8 of those 10, with the remainder spread across 2 other categories. They are less corroborated than the beat average, carrying 2.1 original sources each against 3.4 for the same window. Negative sentiment reaches 20% here, compared with 16% across the 785-story beat baseline for the same window. That works out to roughly 0.3 stories per week across a 202-day span. Johnson & Johnson is most often covered alongside Protagonist Therapeutics, which appears in 2 of these 10 stories. The 5.8 average consequence score is below the beat benchmark of 6.1 in the same window. We currently track 10 Biotech stories that mention Johnson & Johnson, published between February 19, 2026 and September 8, 2026.
Computed from the 10 stories linked to this entity, with beat comparisons drawn from all 785 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Johnson & Johnson. Shared-story counts are live from our verified record — not editorial picks.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
BofA Price Target Hike
Bank of America increases price target, highlighting R&D productivity and MedTech growth.
Fast-Track Approval
USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
12-Month High
JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.
TGA Approval
Australian regulatory body approves the Virtual Nodule Clinic for clinical use.
Pipeline Update
Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Manufacturing Expansion
Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.
FY 2025 Earnings
Legend Biotech reports full-year results and commercial highlights.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Series A Funding
Company raises $14M to scale its AI clinical platform globally.
FDA Clearance
Optellum receives first-of-its-kind FDA clearance for AI lung cancer decision support.
Protagonist's board authorized a $300 million repurchase, backed by $849.5 million in cash and royalty streams from two FDA-approved drugs. For biotech observers, the move marks a shift from cash burn to capital return as partnered products generate milestone and royalty income.
Source: finanznachrichten.de · Seeking Alpha
Colorado’s distribution of $12 million to 27 groups from opioid settlement funds is the latest reminder of pharma’s enduring financial and reputational liabilities. The grants, part of a broader $700M+ state settlement, fuel prevention programs while underscoring that litigation costs continue to ripple through the industry.
Source: kjct8.com
The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
Source: 1190talkradio.iheart.com · manilatimes.net
The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Source: fox5atlanta.com · fox32chicago.com
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
Source: insidermonkey.com · seekingalpha.com
Johnson & Johnson is linked from 10 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
